Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1845, Issue 1, 2014, Pages 1-19

  Fang, Bernard A ^a   Kovačević, Žaklina ^a   Park, Kyung Chan ^a   Kalinowski, Danuta S ^a   Jansson, Patric J ^a   Lane, Darius J R ^a   Sahni, Sumit ^a   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Metastasis suppressor; N myc down regulated gene 1; Thiosemicarbazone

Indexed keywords

2 HYDROXY 1 NAPHTHALDEHYDE ISONICOTINOYLHYDRAZONE; 2 PYRIDYLKETONE 4 CYCLOHEXYL 4 METHYL 3 THIOSEMICARBAZONE; 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; 3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; DEFEROXAMINE; GEMCITABINE; IRINOTECAN; IRON CHELATING AGENT; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN NDRG1; PROTEIN P53; TRYPSIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; CARDIOTOXICITY; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CHEMOSENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; EMBRYO DEVELOPMENT; HUMAN; IMMUNE RESPONSE; LIPOGENESIS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOLECULARLY TARGETED THERAPY; MYELINATION; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; STRESS; TUMOR GROWTH; TUMOR VASCULARIZATION;

2-HYDROXY-1-NAPHTHALDEHYDE ISONICOTINOYL HYDRAZONE; 70-KDA HEAT SHOCK COGNATE PROTEIN; AKT; CHARCOT-MARIE-TOOTH DISEASE, TYPE 4D; CMT4D; CPT-11; DEFEROXAMINE (OR DESFERRIOXAMINE B); DFO; DI-2-PYRIDYLKETONE 4,4-DIMETHYL-3-THIOSEMICARBAZONE; DI-2-PYRIDYLKETONE 4-CYCLOHEXYL-4-METHYL-3-THIOSEMICARBAZONE; DI-2-PYRIDYLKETONE THIOSEMICARBAZONE; DP44MT; DPC; DPT; EARLY GROWTH FACTOR-1; ECM; EGR1; ERG-1; ETS; EXTRACELLULAR MATRIX; HDL-C; HEREDITARY MOTOR AND SENSORY NEUROPATHY-LOM; HIF-1Α; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; HMSNL; HSC70; HTE; HUMAN TRACHEAL EPITHELIAL CELL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELL; HUVEC; HYPOXIA INDUCIBLE FACTOR-1Α; IL; INTERLEUKIN; IRINOTECAN; LDL; LOW-DENSITY LIPOPROTEIN; LPC; LYSOPHOSPHATIDYLCHOLINE; MATRIX METALLOPROTEINASE; METASTASIS SUPPRESSOR; MMP; N-MYC DOWN-REGULATED GENE 1; N-MYC DOWN-STREAM REGULATED GENE 1; NDRG1; NF-ΚB; NIH; NUCLEAR FACTOR-ΚB; PAR-1; PHOSPHATASE AND TENSIN HOMOLOGUE DELETED ON CHROMOSOME 10; PHOSPHORYLATED MYOSIN LIGHT CHAIN 2; PKA; PMLC2; PREC; PROSTATE EPITHELIAL CELL; PROTEASE ACTIVATED RECEPTOR; PROTEIN KINASE A; PROTEIN KINASE B; PROTEIN KINASE C; PTEN; PVHL; REACTIVE OXYGEN SPECIES; RHO-ASSOCIATED, COILED-COIL CONTAINING PROTEIN KINASE 1 (ROCK1); ROCK1; ROS; SERUM- AND GLUCOCORTICOID-INDUCED KINASE; SGK; T-CELL FACTOR/LYMPHOID ENHANCER-BINDING FACTOR; TAT; TAT2; TCF/LEF; THIAMINE TRIPHOSPHATASE; THIOSEMICARBAZONE; THTPA; TUMOUR-ASSOCIATED TRYPSINOGEN; TUMOUR-ASSOCIATED TRYPSINOGEN-2; V-ETS AVIAN ERYTHROBLASTOSIS VIRUS E26 ONCOGENE HOMOLOGUE; V-ETS AVIAN ERYTHROBLASTOSIS VIRUS E26 ONCOGENE HOMOLOGUE 2; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF; VON HIPPEL-LINDAU PROTEIN;

AMINO ACID SEQUENCE; ANIMALS; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; EMBRYONIC DEVELOPMENT; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; TRYPSIN; TUMOR SUPPRESSOR PROTEINS;

EID: 84890028605     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.11.002     Document Type: Review

References (300)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.
2. Chung C.H., Bernard P.S., Perou C.M. Molecular portraits and the family tree of cancer. Nat. Genet. 2002, 32:533-540. (Suppl.).
3. Nwosu V., Carpten J., Trent J.M., Sheridan R. Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum. Mol. Genet. 2001, 10:2313-2318.
4. Singh D., Febbo P.G., Ross K., Jackson D.G., Manola J., Ladd C., Tamayo P., Renshaw A.A., D'Amico A.V., Richie J.P., Lander E.S., Loda M., Kantoff P.W., Golub T.R., Sellers W.R. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002, 1:203-209.
5. Ding L., Ley T.J., Larson D.E., Miller C.A., Koboldt D.C., Welch J.S., Ritchey J.K., Young M.A., Lamprecht T., McLellan M.D., McMichael J.F., Wallis J.W., Lu C., Shen D., Harris C.C., Dooling D.J., Fulton R.S., Fulton L.L., Chen K., Schmidt H., Kalicki-Veizer J., Magrini V.J., Cook L., McGrath S.D., Vickery T.L., Wendl M.C., Heath S., Watson M.A., Link D.C., Tomasson M.H., Shannon W.D., Payton J.E., Kulkarni S., Westervelt P., Walter M.J., Graubert T.A., Mardis E.R., Wilson R.K., DiPersio J.F. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.
6. Gerlinger M., Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br. J. Cancer 2010, 103:1139-1143.
7. Longo D.L. Tumor heterogeneity and personalized medicine. N. Engl. J. Med. 2012, 366:956-957.
8. Navin N., Kendall J., Troge J., Andrews P., Rodgers L., McIndoo J., Cook K., Stepansky A., Levy D., Esposito D., Muthuswamy L., Krasnitz A., McCombie W.R., Hicks J., Wigler M. Tumour evolution inferred by single-cell sequencing. Nature 2011, 472:90-94.
9. Ruiz C., Lenkiewicz E., Evers L., Holley T., Robeson A., Kiefer J., Demeure M.J., Hollingsworth M.A., Shen M., Prunkard D., Rabinovitch P.S., Zellweger T., Mousses S., Trent J.M., Carpten J.D., Bubendorf L., Von Hoff D., Barrett M.T. Advancing a clinically relevant perspective of the clonal nature of cancer. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12054-12059.
10. Saunders N.A., Simpson F., Thompson E.W., Hill M.M., Endo-Munoz L., Leggatt G., Minchin R.F., Guminski A. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol. Med. 2012, 4:675-684.
11. Xu X., Hou Y., Yin X., Bao L., Tang A., Song L., Li F., Tsang S., Wu K., Wu H., He W., Zeng L., Xing M., Wu R., Jiang H., Liu X., Cao D., Guo G., Hu X., Gui Y., Li Z., Xie W., Sun X., Shi M., Cai Z., Wang B., Zhong M., Li J., Lu Z., Gu N., Zhang X., Goodman L., Bolund L., Wang J., Yang H., Kristiansen K., Dean M., Li Y., Wang J. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 2012, 148:886-895.
12. Chang S.S. Treatment options for hormone-refractory prostate cancer. Rev. Urol. 2007, 9(Suppl. 2):S13-S18.
13. Wu Y., Rosenberg J.E., Taplin M.E. Novel agents and new therapeutics in castration-resistant prostate cancer. Curr. Opin. Oncol. 2011, 23:290-296.
14. Stafford L.J., Vaidya K.S., Welch D.R. Metastasis suppressors genes in cancer. Int. J. Biochem. Cell Biol. 2008, 40:874-891.
15. Sleeman J., Steeg P.S. Cancer metastasis as a therapeutic target. Eur. J. Cancer 2010, 46:1177-1180.
16. Talmadge J.E., Fidler I.J. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010, 70:5649-5669.
17. Gonzalgo M.L., Isaacs W.B. Molecular pathways to prostate cancer. J. Urol. 2003, 170:2444-2452.
18. Shand R.L., Gelmann E.P. Molecular biology of prostate-cancer pathogenesis. Curr. Opin. Urol. 2006, 16:123-131.
19. Valastyan S., Weinberg R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292.
20. Yokota J. Tumor progression and metastasis. Carcinogenesis 2000, 21:497-503.
21. Sun B., Chu D., Li W., Chu X., Li Y., Wei D., Li H. Decreased expression of NDRG1 in glioma is related to tumor progression and survival of patients. J. Neurooncol. 2009, 94:213-219.
22. Bandyopadhyay S., Pai S.K., Hirota S., Hosobe S., Takano Y., Saito K., Piquemal D., Commes T., Watabe M., Gross S.C., Wang Y., Ran S., Watabe K. Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene 2004, 23:5675-5681.
23. Bandyopadhyay S., Pai S.K., Hirota S., Hosobe S., Tsukada T., Miura K., Takano Y., Saito K., Commes T., Piquemal D., Watabe M., Gross S., Wang Y., Huggenvik J., Watabe K. PTEN up-regulates the tumor metastasis suppressor gene Drg-1 in prostate and breast cancer. Cancer Res. 2004, 64:7655-7660.
24. van Belzen N., Dinjens W.N., Diesveld M.P., Groen N.A., van der Made A.C., Nozawa Y., Vlietstra R., Trapman J., Bosman F.T. A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms. Lab. Invest. 1997, 77:85-92.
25. Guan R.J., Ford H.L., Fu Y., Li Y., Shaw L.M., Pardee A.B. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res. 2000, 60:749-755.
26. Shah M.A., Kemeny N., Hummer A., Drobnjak M., Motwani M., Cordon-Cardo C., Gonen M., Schwartz G.K. Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes. Clin. Cancer Res. 2005, 11:3296-3302.
27. Strzelczyk B., Szulc A., Rzepko R., Kitowska A., Skokowski J., Szutowicz A., Pawelczyk T. Identification of high-risk stage II colorectal tumors by combined analysis of the NDRG1 gene expression and the depth of tumor invasion. Ann. Surg. Oncol. 2009, 16:1287-1294.
28. Koshiji M., Kumamoto K., Morimura K., Utsumi Y., Aizawa M., Hoshino M., Ohki S., Takenoshita S., Costa M., Commes T., Piquemal D., Harris C.C., Tchou-Wong K.M. Correlation of N-myc downstream-regulated gene 1 expression with clinical outcomes of colorectal cancer patients of different race/ethnicity. World J. Gastroenterol. 2007, 13:2803-2810.
29. Ando T., Ishiguro H., Kimura M., Mitsui A., Kurehara H., Sugito N., Tomoda K., Mori R., Takashima N., Ogawa R., Fujii Y., Kuwabara Y. Decreased expression of NDRG1 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma. Dis. Esophagus 2006, 19:454-458.
30. Maruyama Y., Ono M., Kawahara A., Yokoyama T., Basaki Y., Kage M., Aoyagi S., Kinoshita H., Kuwano M. Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res. 2006, 66:6233-6242.
31. Bandyopadhyay S., Pai S.K., Gross S.C., Hirota S., Hosobe S., Miura K., Saito K., Commes T., Hayashi S., Watabe M., Watabe K. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res. 2003, 63:1731-1736.
32. Masuda K., Ono M., Okamoto M., Morikawa W., Otsubo M., Migita T., Tsuneyoshi M., Okuda H., Shuin T., Naito S., Kuwano M. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells. Int. J. Cancer 2003, 105:803-810.
33. Yan X., Chua M.S., Sun H., So S. N-Myc down-regulated gene 1 mediates proliferation, invasion, and apoptosis of hepatocellular carcinoma cells. Cancer Lett. 2008, 262:133-142.
34. Chua M.S., Sun H., Cheung S.T., Mason V., Higgins J., Ross D.T., Fan S.T., So S. Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. Mod. Pathol. 2007, 20:76-83.
35. Akiba J., Ogasawara S., Kawahara A., Nishida N., Sanada S., Moriya F., Kuwano M., Nakashima O., Yano H. N-myc downstream regulated gene 1 (NDRG1)/Cap43 enhances portal vein invasion and intrahepatic metastasis in human hepatocellular carcinoma. Oncol. Rep. 2008, 20:1329-1335.
36. Chang J.T., Wang H.M., Chang K.W., Chen W.H., Wen M.C., Hsu Y.M., Yung B.Y., Chen I.H., Liao C.T., Hsieh L.L., Cheng A.J. Identification of differentially expressed genes in oral squamous cell carcinoma (OSCC): overexpression of NPM, CDK1 and NDRG1 and underexpression of CHES1. Int. J. Cancer 2005, 114:942-949.
37. Dang C., Gottschling M., Manning K., O'Currain E., Schneider S., Sterry W., Stockfleth E., Nindl I. Identification of dysregulated genes in cutaneous squamous cell carcinoma. Oncol. Rep. 2006, 16:513-519.
38. Song J.Y., Lee J.K., Lee N.W., Jung H.H., Kim S.H., Lee K.W. Microarray analysis of normal cervix, carcinoma in situ, and invasive cervical cancer: identification of candidate genes in pathogenesis of invasion in cervical cancer. Int. J. Gynecol. Cancer 2008, 18:1051-1059.
39. Nishio S., Ushijima K., Tsuda N., Takemoto S., Kawano K., Yamaguchi T., Nishida N., Kakuma T., Tsuda H., Kasamatsu T., Sasajima Y., Kage M., Kuwano M., Kamura T. Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma. Cancer Lett. 2008, 264:36-43.
40. Kokame K., Kato H., Miyata T. Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis. GRP78/BiP and novel genes. J. Biol. Chem. 1996, 271:29659-29665.
41. Kurdistani S.K., Arizti P., Reimer C.L., Sugrue M.M., Aaronson S.A., Lee S.W. Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res. 1998, 58:4439-4444.
42. Zhou D., Salnikow K., Costa M. Cap43, a novel gene specifically induced by Ni2+ compounds. Cancer Res. 1998, 58:2182-2189.
43. Park H., Adams M.A., Lachat P., Bosman F., Pang S.C., Graham C.H. Hypoxia induces the expression of a 43-kDa protein (PROXY-1) in normal and malignant cells. Biochem. Biophys. Res. Commun. 2000, 276:321-328.
44. Li J., Kretzner L. The growth-inhibitory Ndrg1 gene is a Myc negative target in human neuroblastomas and other cell types with overexpressed N- or c-myc. Mol. Cell. Biochem. 2003, 250:91-105.
45. Shimono A., Okuda T., Kondoh H. N-myc-dependent repression of ndr1, a gene identified by direct subtraction of whole mouse embryo cDNAs between wild type and N-myc mutant. Mech. Dev. 1999, 83:39-52.
46. Lin T.M., Chang C. Cloning and characterization of TDD5, an androgen target gene that is differentially repressed by testosterone and dihydrotestosterone. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:4988-4993.
47. Kräuter-Canham R., Bronner R., Evrard J.-L., Hahne G., Friedt W., Steinmetz A. A transmitting tissue- and pollen-expressed protein from sunflower with sequence similarity to the human RTP protein. Plant Sci. 1997, 129:191-202.
48. Shaw E., McCue L.A., Lawrence C.E., Dordick J.S. Identification of a novel class in the alpha/beta hydrolase fold superfamily: the N-myc differentiation-related proteins. Proteins 2002, 47:163-168.
49. Zhou R.H., Kokame K., Tsukamoto Y., Yutani C., Kato H., Miyata T. Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics 2001, 73:86-97.
50. Qu X., Zhai Y., Wei H., Zhang C., Xing G., Yu Y., He F. Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol. Cell. Biochem. 2002, 229:35-44.
51. Melotte V., Qu X., Ongenaert M., van Criekinge W., de Bruine A.P., Baldwin H.S., van Engeland M. The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications. FASEB J. 2010, 24:4153-4166.
52. Bhaduri A., Krishnaswamy L., Ullal G.R., Panicker M.M., Sowdhamini R. Fold prediction and comparative modeling of Bdm1: a probable alpha/beta hydrolase associated with hot water epilepsy. J. Mol. Model. 2003, 9:3-8.
53. Kovacevic Z., Richardson D.R. The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis 2006, 27:2355-2366.
54. Kalaydjieva L., Hallmayer J., Chandler D., Savov A., Nikolova A., Angelicheva D., King R.H., Ishpekova B., Honeyman K., Calafell F., Shmarov A., Petrova J., Turnev I., Hristova A., Moskov M., Stancheva S., Petkova I., Bittles A.H., Georgieva V., Middleton L., Thomas P.K. Gene mapping in gypsies identifies a novel demyelinating neuropathy on chromosome 8q24. Nat. Genet. 1996, 14:214-217.
55. van Belzen N., Dinjens W.N., Eussen B.H., Bosman F.T. Expression of differentiation-related genes in colorectal cancer: possible implications for prognosis. Histol. Histopathol. 1998, 13:1233-1242.
56. Thierry-Mieg D., Thierry-Mieg J. AceView: a comprehensive cDNA-supported gene and transcripts annotation. Genome Biol. 2006, 7(Suppl. 1):11-14. (S12).
57. Cher M.L., Bova G.S., Moore D.H., Small E.J., Carroll P.R., Pin S.S., Epstein J.I., Isaacs W.B., Jensen R.H. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 1996, 56:3091-3102.
58. Angst E., Dawson D.W., Nguyen A., Park J., Go V.L., Reber H.A., Hines O.J., Eibl G. Epigenetic regulation affects N-myc downstream-regulated gene 1 expression indirectly in pancreatic cancer cells. Pancreas 2010, 39:675-679.
59. Williams K., Fernandez S., Stien X., Ishii K., Love H.D., Lau Y.F., Roberts R.L., Hayward S.W. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate 2005, 63:369-384.
60. Kim Y.H., Girard L., Giacomini C.P., Wang P., Hernandez-Boussard T., Tibshirani R., Minna J.D., Pollack J.R. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene 2006, 25:130-138.
61. Zhang J., Chen S., Zhang W., Zhang J., Liu X., Shi H., Che H., Wang W., Li F., Yao L. Human differentiation-related gene NDRG1 is a Myc downstream-regulated gene that is repressed by Myc on the core promoter region. Gene 2008, 417:5-12.
62. Hwang J., Kim Y., Kang H.B., Jaroszewski L., Deacon A.M., Lee H., Choi W.C., Kim K.J., Kim C.H., Kang B.S., Lee J.O., Oh T.K., Kim J.W., Wilson I.A., Kim M.H. Crystal structure of the human N-Myc downstream-regulated gene 2 protein provides insight into its role as a tumor suppressor. J. Biol. Chem. 2011, 286:12450-12460.
63. Murray J.T., Campbell D.G., Morrice N., Auld G.C., Shpiro N., Marquez R., Peggie M., Bain J., Bloomberg G.B., Grahammer F., Lang F., Wulff P., Kuhl D., Cohen P. Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem. J. 2004, 384:477-488.
64. Murray J.T., Cummings L.A., Bloomberg G.B., Cohen P. Identification of different specificity requirements between SGK1 and PKBalpha. FEBS Lett. 2005, 579:991-994.
65. Inglis S.K., Gallacher M., Brown S.G., McTavish N., Getty J., Husband E.M., Murray J.T., Wilson S.M. SGK1 activity in Na+absorbing airway epithelial cells monitored by assaying NDRG1-Thr346/356/366 phosphorylation. Pflugers Arch. 2009, 457:1287-1301.
66. Hoang B., Frost P., Shi Y., Belanger E., Benavides A., Pezeshkpour G., Cappia S., Guglielmelli T., Gera J., Lichtenstein A. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 2010, 116:4560-4568.
67. Sahin P., McCaig C., Jeevahan J., Murray J.T., Hainsworth A.H. The cell survival kinase SGK1 and its targets FOXO3a and NDRG1 in aged human brain. Neuropathol. Appl. Neurobiol. 2013, 39:623-633.
68. Segawa T., Nau M.E., Xu L.L., Chilukuri R.N., Makarem M., Zhang W., Petrovics G., Sesterhenn I.A., McLeod D.G., Moul J.W., Vahey M., Srivastava S. Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene 2002, 21:8749-8758.
69. Xu B., Lin L., Rote N.S. Identification of a stress-induced protein during human trophoblast differentiation by differential display analysis. Biol. Reprod. 1999, 61:681-686.
70. Matsugaki T., Zenmyo M., Hiraoka K., Fukushima N., Shoda T., Komiya S., Ono M., Kuwano M., Nagata K. N-myc downstream-regulated gene 1/Cap43 expression promotes cell differentiation of human osteosarcoma cells. Oncol. Rep. 2010, 24:721-725.
71. McCaig C., Potter L., Abramczyk O., Murray J.T. Phosphorylation of NDRG1 is temporally and spatially controlled during the cell cycle. Biochem. Biophys. Res. Commun. 2011, 411:227-234.
72. Murakami Y., Hosoi F., Izumi H., Maruyama Y., Ureshino H., Watari K., Kohno K., Kuwano M., Ono M. Identification of sites subjected to serine/threonine phosphorylation by SGK1 affecting N-myc downstream-regulated gene 1 (NDRG1)/Cap43-dependent suppression of angiogenic CXC chemokine expression in human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2010, 396:376-381.
73. Moore B.B., Arenberg D.A., Stoy K., Morgan T., Addison C.L., Morris S.B., Glass M., Wilke C., Xue Y.Y., Sitterding S., Kunkel S.L., Burdick M.D., Strieter R.M. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am. J. Pathol. 1999, 154:1503-1512.
74. Waugh D.J., Wilson C., Seaton A., Maxwell P.J. Multi-faceted roles for CXC-chemokines in prostate cancer progression. Front. Biosci. 2008, 13:4595-4604.
75. Zoroddu M.A., Kowalik-Jankowska T., Kozlowski H., Salnikow K., Costa M. Ni(II) and Cu(II) binding with a 14-aminoacid sequence of Cap43 protein, TRSRSHTSEGTRSR. J. Inorg. Biochem. 2001, 84:47-54.
76. Zoroddu M.A., Peana M., Kowalik-Jankowska T., Kozlowski H., Costa M. Nickel(II) binding to Cap43 protein fragments. J. Inorg. Biochem. 2004, 98:931-939.
77. Zoroddu M.A., Peana M., Medici S., Anedda R. An NMR study on nickel binding sites in Cap43 protein fragments. Dalton Trans. 2009, 5523-5534.
78. Zoroddu M.A., Kowalik-Jankowska T., Medici S., Peana M., Kozlowski H. Copper(II) binding to Cap43 protein fragments. Dalton Trans. 2008, 6127-6134.
79. Stein S., Thomas E.K., Herzog B., Westfall M.D., Rocheleau J.V., Jackson R.S., Wang M., Liang P. NDRG1 is necessary for p53-dependent apoptosis. J. Biol. Chem. 2004, 279:48930-48940.
80. Zhang A.H., Rao J.N., Zou T., Liu L., Marasa B.S., Xiao L., Chen J., Turner D.J., Wang J.Y. p53-dependent NDRG1 expression induces inhibition of intestinal epithelial cell proliferation but not apoptosis after polyamine depletion. Am. J. Physiol. Cell Physiol. 2007, 293:C379-C389.
81. Combet C., Blanchet C., Geourjon C., Deleage G. NPS@: network protein sequence analysis. Trends Biochem. Sci. 2000, 25:147-150.
82. Rost B., Casadio R., Fariselli P., Sander C. Transmembrane helices predicted at 95% accuracy. Protein Sci. 1995, 4:521-533.
83. Sugiki T., Murakami M., Taketomi Y., Kikuchi-Yanoshita R., Kudo I. N-myc downregulated gene 1 is a phosphorylated protein in mast cells. Biol. Pharm. Bull. 2004, 27:624-627.
84. Agarwala K.L., Kokame K., Kato H., Miyata T. Phosphorylation of RTP, an ER stress-responsive cytoplasmic protein. Biochem. Biophys. Res. Commun. 2000, 272:641-647.
85. Bandyopadhyay S., Wang Y., Zhan R., Pai S.K., Watabe M., Iiizumi M., Furuta E., Mohinta S., Liu W., Hirota S., Hosobe S., Tsukada T., Miura K., Takano Y., Saito K., Commes T., Piquemal D., Hai T., Watabe K. The tumor metastasis suppressor gene Drg-1 down-regulates the expression of activating transcription factor 3 in prostate cancer. Cancer Res. 2006, 66:11983-11990.
86. Fernandez P.C., Frank S.R., Wang L., Schroeder M., Liu S., Greene J., Cocito A., Amati B. Genomic targets of the human c-Myc protein. Genes Dev. 2003, 17:1115-1129.
87. Patel J.H., Loboda A.P., Showe M.K., Showe L.C., McMahon S.B. Analysis of genomic targets reveals complex functions of MYC. Nat. Rev. Cancer 2004, 4:562-568.
88. Han L.L., Hou L., Zhou M.J., Ma Z.L., Lin D.L., Wu L., Ge Y.L. Aberrant NDRG1 methylation associated with its decreased expression and clinicopathological significance in breast cancer. J. Biomed. Sci. 2013, 20:52.
89. Chang X., Zhang S., Ma J., Li Z., Zhi Y., Chen J., Lu Y., Dai D. Association of NDRG1 gene promoter methylation with reduced NDRG1 expression in gastric cancer cells and tissue specimens. Cell Biochem. Biophys. 2013, 66:93-101.
90. Li Q., Chen H. Transcriptional silencing of N-Myc downstream-regulated gene 1 (NDRG1) in metastatic colon cancer cell line SW620. Clin. Exp. Metastasis 2011, 28:127-135.
91. Todd A.E., Orengo C.A., Thornton J.M. Sequence and structural differences between enzyme and nonenzyme homologs. Structure 2002, 10:1435-1451.
92. Berger P., Sirkowski E.E., Scherer S.S., Suter U. Expression analysis of the N-Myc downstream-regulated gene 1 indicates that myelinating Schwann cells are the primary disease target in hereditary motor and sensory neuropathy-Lom. Neurobiol. Dis. 2004, 17:290-299.
93. Ghalayini M.K., Dong Q., Richardson D.R., Assinder S.J. Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but not normal prostate epithelial cells. Biosci. Rep. 2013, 33:451-461.
94. Chen Z., Zhang D., Yue F., Zheng M., Kovacevic Z., Richardson D.R. The iron chelators Dp44mT and DFO inhibit TGF-beta-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J. Biol. Chem. 2012, 287:17016-17028.
95. Dixon K.M., Lui G.Y., Kovacevic Z., Zhang D., Yao M., Chen Z., Dong Q., Assinder S.J., Richardson D.R. Dp44mT targets the AKT, TGF-beta and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. Br. J. Cancer 2013, 108:409-419.
96. Kovacevic Z., Chikhani S., Lovejoy D.B., Richardson D.R. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol. Pharmacol. 2011, 80:598-609.
97. Lui G.Y., Obeidy P., Ford S.J., Tselepis C., Sharp D.M., Jansson P.J., Kalinowski D.S., Kovacevic Z., Lovejoy D.B., Richardson D.R. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol. Pharmacol. 2013, 83:179-190.
98. Pflueger D., Rickman D.S., Sboner A., Perner S., LaFargue C.J., Svensson M.A., Moss B.J., Kitabayashi N., Pan Y., de la Taille A., Kuefer R., Tewari A.K., Demichelis F., Chee M.S., Gerstein M.B., Rubin M.A. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 2009, 11:804-811.
99. Wakisaka Y., Furuta A., Masuda K., Morikawa W., Kuwano M., Iwaki T. Cellular distribution of NDRG1 protein in the rat kidney and brain during normal postnatal development. J. Histochem. Cytochem. 2003, 51:1515-1525.
100. Nakai K., Horton P. PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends Biochem. Sci. 1999, 24:34-36.
101. Artimo P., Jonnalagedda M., Arnold K., Baratin D., Csardi G., de Castro E., Duvaud S., Flegel V., Fortier A., Gasteiger E., Grosdidier A., Hernandez C., Ioannidis V., Kuznetsov D., Liechti R., Moretti S., Mostaguir K., Redaschi N., Rossier G., Xenarios I., Stockinger H. ExPASy: SIB bioinformatics resource portal. Nucleic Acids Res. 2012, 40:W597-W603.
102. Wilkins M.R., Gasteiger E., Bairoch A., Sanchez J.C., Williams K.L., Appel R.D., Hochstrasser D.F. Protein identification and analysis tools in the ExPASy server. Methods Mol. Biol. 1999, 112:531-552.
103. Bjartell A., Paju A., Zhang W.M., Gadaleanu V., Hansson J., Landberg G., Stenman U.H. Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. Prostate 2005, 64:29-39.
104. Darmoul D., Marie J.C., Devaud H., Gratio V., Laburthe M. Initiation of human colon cancer cell proliferation by trypsin acting at protease-activated receptor-2. Br. J. Cancer 2001, 85:772-779.
105. Hotakainen K., Bjartell A., Sankila A., Jarvinen R., Paju A., Rintala E., Haglund C., Stenman U.H. Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. Int. J. Oncol. 2006, 28:95-101.
106. Miyata S., Koshikawa N., Higashi S., Miyagi Y., Nagashima Y., Yanoma S., Kato Y., Yasumitsu H., Miyazaki K. Expression of trypsin in human cancer cell lines and cancer tissues and its tight binding to soluble form of Alzheimer amyloid precursor protein in culture. J. Biochem. 1999, 125:1067-1076.
107. Paju A., Sorsa T., Tervahartiala T., Koivunen E., Haglund C., Leminen A., Wahlstrom T., Salo T., Stenman U.H. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. Br. J. Cancer 2001, 84:1363-1371.
108. Sorsa T., Salo T., Koivunen E., Tyynela J., Konttinen Y.T., Bergmann U., Tuuttila A., Niemi E., Teronen O., Heikkila P., Tschesche H., Leinonen J., Osman S., Stenman U.H. Activation of type IV procollagenases by human tumor-associated trypsin-2. J. Biol. Chem. 1997, 272:21067-21074.
109. Hockla A., Miller E., Salameh M.A., Copland J.A., Radisky D.C., Radisky E.S. PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer. Mol. Cancer Res. 2012, 10:1555-1566.
110. Bae D.H., Jansson P.J., Huang M.L., Kovacevic Z., Kalinowski D., Lee C.S., Sahni S., Richardson D.R. The role of NDRG1 in the pathology and potential treatment of human cancers. J. Clin. Pathol. 2013, 66:911-917.
111. Kovacevic Z., Chikhani S., Lui G.Y., Sivagurunathan S., Richardson D.R. The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways. Antioxid. Redox Signal. 2013, 18:874-887.
112. Sun J., Zhang D., Bae D.H., Sahni S., Jansson P., Zheng Y., Zhao Q., Yue F., Zheng M., Kovacevic Z., Richardson D.R. Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. Carcinogenesis 2013, 34:1943-1954.
113. Jiang G., Cao F., Ren G., Gao D., Bhakta V., Zhang Y., Cao H., Dong Z., Zang W., Zhang S., Wong H.H., Hiley C., Crnogorac-Jurcevic T., Lemoine N.R., Wang Y. PRSS3 promotes tumour growth and metastasis of human pancreatic cancer. Gut 2010, 59:1535-1544.
114. Gondi C.S., Rao J.S. Cathepsin B as a cancer target. Expert Opin. Ther. Targets 2013, 17:281-291.
115. Hockla A., Radisky D.C., Radisky E.S. Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. Breast Cancer Res. Treat. 2010, 124:27-38.
116. Szmola R., Kukor Z., Sahin-Toth M. Human mesotrypsin is a unique digestive protease specialized for the degradation of trypsin inhibitors. J. Biol. Chem. 2003, 278:48580-48589.
117. Nyberg P., Ylipalosaari M., Sorsa T., Salo T. Trypsins and their role in carcinoma growth. Exp. Cell Res. 2006, 312:1219-1228.
118. Stenman U.H., Koivunen E., Vuento M. Characterization of a tumor-associated serine protease. Biol. Chem. 1988, 369:9-14. (Suppl.).
119. Ohta T., Terada T., Nagakawa T., Tajima H., Itoh H., Fonseca L., Miyazaki I. Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions. Br. J. Cancer 1994, 69:152-156.
120. Koivunen E., Saksela O., Itkonen O., Osman S., Huhtala M.L., Stenman U.H. Human colon carcinoma, fibrosarcoma and leukemia cell lines produce tumor-associated trypsinogen. Int. J. Cancer 1991, 47:592-596.
121. Oyama K., Ohta T., Nishimura G.I., Elnemr A., Yasui T., Fujimura T., Fushida S., Kitagawa H., Kayahara M., Terada T., Miwa K. Trypsinogen expression in colorectal cancers. Int. J. Mol. Med. 2000, 6:543-548.
122. Kawano N., Osawa H., Ito T., Nagashima Y., Hirahara F., Inayama Y., Nakatani Y., Kimura S., Kitajima H., Koshikawa N., Miyazaki K., Kitamura H. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum. Pathol. 1997, 28:613-622.
123. Koivunen E., Itkonen O., Halila H., Stenman U.H. Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2. Cancer Res. 1990, 50:2375-2378.
124. Lachat P., Shaw P., Gebhard S., van Belzen N., Chaubert P., Bosman F.T. Expression of NDRG1, a differentiation-related gene, in human tissues. Histochem. Cell Biol. 2002, 118:399-408.
125. Ulrix W., Swinnen J.V., Heyns W., Verhoeven G. The differentiation-related gene 1, Drg1, is markedly upregulated by androgens in LNCaP prostatic adenocarcinoma cells. FEBS Lett. 1999, 455:23-26.
126. Cangul H., Salnikow K., Yee H., Zagzag D., Commes T., Costa M. Enhanced expression of a novel protein in human cancer cells: a potential aid to cancer diagnosis. Cell Biol. Toxicol. 2002, 18:87-96.
127. Kachhap S.K., Faith D., Qian D.Z., Shabbeer S., Galloway N.L., Pili R., Denmeade S.R., DeMarzo A.M., Carducci M.A. The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. PLoS One 2007, 2:e844.
128. Taketomi Y., Sunaga K., Tanaka S., Nakamura M., Arata S., Okuda T., Moon T.C., Chang H.W., Sugimoto Y., Kokame K., Miyata T., Murakami M., Kudo I. Impaired mast cell maturation and degranulation and attenuated allergic responses in Ndrg1-deficient mice. J. Immunol. 2007, 178:7042-7053.
129. Pecheur E.I., Martin I., Maier O., Bakowsky U., Ruysschaert J.M., Hoekstra D. Phospholipid species act as modulators in p97/p47-mediated fusion of Golgi membranes. Biochemistry 2002, 41:9813-9823.
130. Zinsmaier K.E., Bronk P. Molecular chaperones and the regulation of neurotransmitter exocytosis. Biochem. Pharmacol. 2001, 62:1-11.
131. Sugiki T., Taketomi Y., Kikuchi-Yanoshita R., Murakami M., Kudo I. Association of N-myc downregulated gene 1 with heat-shock cognate protein 70 in mast cells. Biol. Pharm. Bull. 2004, 27:628-633.
132. Okuda T., Kondoh H. Identification of new genes ndr2 and ndr3 which are related to Ndr1/RTP/Drg1 but show distinct tissue specificity and response to N-myc. Biochem. Biophys. Res. Commun. 1999, 266:208-215.
133. Horton P., Park K.J., Obayashi T., Fujita N., Harada H., Adams-Collier C.J., Nakai K. WoLF PSORT: protein localization predictor. Nucleic Acids Res. 2007, 35:W585-W587.
134. Gomez-Casero E., Navarro M., Rodriguez-Puebla M.L., Larcher F., Paramio J.M., Conti C.J., Jorcano J.L. Regulation of the differentiation-related gene Drg-1 during mouse skin carcinogenesis. Mol. Carcinog. 2001, 32:100-109.
135. Hunter M., Angelicheva D., Tournev I., Ingley E., Chan D.C., Watts G.F., Kremensky I., Kalaydjieva L. NDRG1 interacts with APO A-I and A-II and is a functional candidate for the HDL-C QTL on 8q24. Biochem. Biophys. Res. Commun. 2005, 332:982-992.
136. Cheng J., Xie H.Y., Xu X., Wu J., Wei X., Su R., Zhang W., Lv Z., Zheng S., Zhou L. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. Cancer Lett. 2011, 310:35-45.
137. Tu L.C., Yan X., Hood L., Lin B. Proteomics analysis of the interactome of N-myc downstream regulated gene 1 and its interactions with the androgen response program in prostate cancer cells. Mol. Cell. Proteomics 2007, 6:575-588.
138. Ellen T.P., Ke Q., Zhang P., Costa M. NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis 2008, 29:2-8.
139. Salnikow K., Kluz T., Costa M. Role of Ca(2+) in the regulation of nickel-inducible Cap43 gene expression. Toxicol. Appl. Pharmacol. 1999, 160:127-132.
140. Cangul H. Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet. 2004, 5:27.
141. Salnikow K., Su W., Blagosklonny M.V., Costa M. Carcinogenic metals induce hypoxia-inducible factor-stimulated transcription by reactive oxygen species-independent mechanism. Cancer Res. 2000, 60:3375-3378.
142. Kovacevic Z., Fu D., Richardson D.R. The iron-regulated metastasis suppressor, Ndrg-1: identification of novel molecular targets. Biochim. Biophys. Acta 2008, 1783:1981-1992.
143. Le N.T., Richardson D.R. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 2004, 104:2967-2975.
144. Krishnan A.V., Shinghal R., Raghavachari N., Brooks J.D., Peehl D.M., Feldman D. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 2004, 59:243-251.
145. Piquemal D., Joulia D., Balaguer P., Basset A., Marti J., Commes T. Differential expression of the RTP/Drg1/Ndr1 gene product in proliferating and growth arrested cells. Biochim. Biophys. Acta 1999, 1450:364-373.
146. Zhang P., Tchou-Wong K.M., Costa M. Egr-1 mediates hypoxia-inducible transcription of the NDRG1 gene through an overlapping Egr-1/Sp1 binding site in the promoter. Cancer Res. 2007, 67:9125-9133.
147. Unoki M., Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 2001, 20:4457-4465.
148. Li W., Zhao Y., Chou I.N. Nickel (Ni2+) enhancement of alpha-tubulin acetylation in cultured 3T3 cells. Toxicol. Appl. Pharmacol. 1996, 140:461-470.
149. Rutherford M.N., Bayly G.R., Matthews B.P., Okuda T., Dinjens W.M., Kondoh H., LeBrun D.P. The leukemogenic transcription factor E2a-Pbx1 induces expression of the putative N-myc and p53 target gene NDRG1 in Ba/F3 cells. Leukemia 2001, 15:362-370.
150. Yu J., Zhang L., Hwang P.M., Rago C., Kinzler K.W., Vogelstein B. Identification and classification of p53-regulated genes. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:14517-14522.
151. Cangul H., Salnikow K., Yee H., Zagzag D., Commes T., Costa M. Enhanced overexpression of an HIF-1/hypoxia-related protein in cancer cells. Environ. Health Perspect. 2002, 110(Suppl. 5):783-788.
152. Lane D.J., Saletta F., Suryo Rahmanto Y., Kovacevic Z., Richardson D.R. N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion. PLoS One 2013, 8:e57273.
153. Chen B., Nelson D.M., Sadovsky Y. N-myc down-regulated gene 1 modulates the response of term human trophoblasts to hypoxic injury. J. Biol. Chem. 2006, 281:2764-2772.
154. Dong Z., Arnold R.J., Yang Y., Park M.H., Hrncirova P., Mechref Y., Novotny M.V., Zhang J.T. Modulation of differentiation-related gene 1 expression by cell cycle blocker mimosine, revealed by proteomic analysis. Mol. Cell. Proteomics 2005, 4:993-1001.
155. Semenza G.L., Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 1992, 12:5447-5454.
156. Yan S.F., Zou Y.S., Gao Y., Zhai C., Mackman N., Lee S.L., Milbrandt J., Pinsky D., Kisiel W., Stern D. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:8298-8303.
157. Kalinowski D.S., Richardson D.R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 2005, 57:547-583.
158. Salnikow K., Kluz T., Costa M., Piquemal D., Demidenko Z.N., Xie K., Blagosklonny M.V. The regulation of hypoxic genes by calcium involves c-Jun/AP-1, which cooperates with hypoxia-inducible factor 1 in response to hypoxia. Mol. Cell. Biol. 2002, 22:1734-1741.
159. Hickok J.R., Sahni S., Mikhed Y., Bonini M.G., Thomas D.D. Nitric oxide suppresses tumor cell migration through N-Myc downstream-regulated gene-1 (NDRG1) expression: role of chelatable iron. J. Biol. Chem. 2011, 286:41413-41424.
160. Hickok J.R., Sahni S., Shen H., Arvind A., Antoniou C., Fung L.W., Thomas D.D. Dinitrosyliron complexes are the most abundant nitric oxide-derived cellular adduct: biological parameters of assembly and disappearance. Free Radic. Biol. Med. 2011, 51:1558-1566.
161. Park Y.K., Ahn D.R., Oh M., Lee T., Yang E.G., Son M., Park H. Nitric oxide donor, (+/-)-S-nitroso-N-acetylpenicillamine, stabilizes transactive hypoxia-inducible factor-1alpha by inhibiting von Hippel-Lindau recruitment and asparagine hydroxylation. Mol. Pharmacol. 2008, 74:236-245.
162. Salnikow K., Aprelikova O., Ivanov S., Tackett S., Kaczmarek M., Karaczyn A., Yee H., Kasprzak K.S., Niederhuber J. Regulation of hypoxia-inducible genes by ETS1 transcription factor. Carcinogenesis 2008, 29:1493-1499.
163. Kyuno J., Fukui A., Michiue T., Asashima M. Identification and characterization of Xenopus NDRG1. Biochem. Biophys. Res. Commun. 2003, 309:52-57.
164. Roh C.R., Budhraja V., Kim H.S., Nelson D.M., Sadovsky Y. Microarray-based identification of differentially expressed genes in hypoxic term human trophoblasts and in placental villi of pregnancies with growth restricted fetuses. Placenta 2005, 26:319-328.
165. Choi S.J., Oh S.Y., Kim J.H., Sadovsky Y., Roh C.R. Increased expression of N-myc downstream-regulated gene 1 (NDRG1) in placentas from pregnancies complicated by intrauterine growth restriction or preeclampsia. Am. J. Obstet. Gynecol. 2007, 196(45):e41-e47.
166. Zhang T., Guo X., Chen Y. Retinoic acid-activated Ndrg1a represses Wnt/beta-catenin signaling to allow Xenopus pancreas, oesophagus, stomach, and duodenum specification. PLoS One 2013, 8:e65058.
167. Kim B.H., Park E.Y., Yoo K.H., Choi K.M., Kim Y., Seong J., Park J.H. N-myc downstream-regulated gene 1 is involved in the regulation of cystogenesis in transgenic mice overexpressing human PKD2 gene. Proteomics 2013, 13:134-141.
168. Kim K.T., Ongusaha P.P., Hong Y.K., Kurdistani S.K., Nakamura M., Lu K.P., Lee S.W. Function of Drg1/Rit42 in p53-dependent mitotic spindle checkpoint. J. Biol. Chem. 2004, 279:38597-38602.
169. Chen S., Han Y.H., Zheng Y., Zhao M., Yan H., Zhao Q., Chen G.Q., Li D. NDRG1 contributes to retinoic acid-induced differentiation of leukemic cells. Leuk. Res. 2009, 33:1108-1113.
170. Taketomi Y., Sugiki T., Saito T., Ishii S., Hisada M., Suzuki-Nishimura T., Uchida M.K., Moon T.C., Chang H.W., Natori Y., Miyazawa S., Kikuchi-Yanoshita R., Murakami M., Kudo I. Identification of NDRG1 as an early inducible gene during in vitro maturation of cultured mast cells. Biochem. Biophys. Res. Commun. 2003, 306:339-346.
171. Kalaydjieva L., Gresham D., Gooding R., Heather L., Baas F., de Jonge R., Blechschmidt K., Angelicheva D., Chandler D., Worsley P., Rosenthal A., King R.H., Thomas P.K. N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom. Am. J. Hum. Genet. 2000, 67:47-58.
172. Okuda T., Kokame K., Miyata T. Differential expression patterns of NDRG family proteins in the central nervous system. J. Histochem. Cytochem. 2008, 56:175-182.
173. Okuda T., Kokame K., Miyata T. Functional analyses of NDRG1, a stress-responsive gene. Seikagaku 2005, 77:630-634.
174. Leonardis L., Zidar J., Popovic M., Timmerman V., Lofgren A., Van Broeckhoven C., Butinar D. Hereditary motor and sensory neuropathy associated with auditory neuropathy in a Gypsy family. Pflugers Arch. 2000, 439:R208-R210.
175. Kalaydjieva L., Nikolova A., Turnev I., Petrova J., Hristova A., Ishpekova B., Petkova I., Shmarov A., Stancheva S., Middleton L., Merlini L., Trogu A., Muddle J.R., King R.H., Thomas P.K. Hereditary motor and sensory neuropathy-Lom, a novel demyelinating neuropathy associated with deafness in gypsies. Clinical, electrophysiological and nerve biopsy findings. Brain 1998, 121(Pt 3):399-408.
176. Dackovic J., Keckarevic-Markovic M., Komazec Z., Rakocevic-Stojanovic V., Lavrnic D., Stevic Z., Ribaric K., Romac S., Apostolski S. Hereditary motor and sensory neuropathy Lom type in a Serbian family. Acta Myol. 2008, 27:59-62.
177. Hunter M., Bernard R., Freitas E., Boyer A., Morar B., Martins I.J., Tournev I., Jordanova A., Guergelcheva V., Ishpekova B., Kremensky I., Nicholson G., Schlotter B., Lochmuller H., Voit T., Colomer J., Thomas P.K., Levy N., Kalaydjieva L. Mutation screening of the N-myc downstream-regulated gene 1 (NDRG1) in patients with Charcot-Marie-Tooth Disease. Hum. Mutat. 2003, 22:129-135.
178. Bruun C.S., Jaderlund K.H., Berendt M., Jensen K.B., Spodsberg E.H., Gredal H., Shelton G.D., Mickelson J.R., Minor K.M., Lohi H., Bjerkas I., Stigen O., Espenes A., Rohdin C., Edlund R., Ohlsson J., Cizinauskas S., Leifsson P.S., Drogemuller C., Moe L., Cirera S., Fredholm M. A Gly98Val mutation in the N-Myc downstream regulated gene 1 (NDRG1) in Alaskan Malamutes with polyneuropathy. PLoS One 2013, 8:e54547.
179. Drogemuller C., Becker D., Kessler B., Kemter E., Tetens J., Jurina K., Jaderlund K.H., Flagstad A., Perloski M., Lindblad-Toh K., Matiasek K. A deletion in the N-myc downstream regulated gene 1 (NDRG1) gene in Greyhounds with polyneuropathy. PLoS One 2010, 5:e11258.
180. Okuda T., Higashi Y., Kokame K., Tanaka C., Kondoh H., Miyata T. Ndrg1-deficient mice exhibit a progressive demyelinating disorder of peripheral nerves. Mol. Cell. Biol. 2004, 24:3949-3956.
181. Pietiainen V., Vassilev B., Blom T., Wang W., Nelson J., Bittman R., Back N., Zelcer N., Ikonen E. NDRG1 functions in LDL receptor trafficking by regulating endosomal recycling and degradation. J. Cell Sci. 2013, 126:3961-3971.
182. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs D.R., Bangdiwala S., Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8-15.
183. Kovacevic Z., Sivagurunathan S., Mangs H., Chikhani S., Zhang D., Richardson D.R. The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis 2011, 32:732-740.
184. Sacks F.M. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am. J. Cardiol. 2002, 90:139-143.
185. Janeway C.A., Travers P., Walport M., Shlomchik M.J. Immunobiology 2001, Garland Science, New York City. 5 ed.
186. Sfanos K.S., De Marzo A.M. Prostate cancer and inflammation: the evidence. Histopathology 2012, 60:199-215.
187. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., Sethi G. Inflammation and cancer: how hot is the link?. Biochem. Pharmacol. 2006, 72:1605-1621.
188. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
189. Lu H., Ouyang W., Huang C. Inflammation, a key event in cancer development. Mol. Cancer Res. 2006, 4:221-233.
190. Nakai Y., Nonomura N. Inflammation and prostate carcinogenesis. Int. J. Urol. 2013, 20:150-160.
191. van Kempen L.C., de Visser K.E., Coussens L.M. Inflammation, proteases and cancer. Eur. J. Cancer 2006, 42:728-734.
192. Tschan M.P., Shan D., Laedrach J., Eyholzer M., Leibundgut E.O., Baerlocher G.M., Tobler A., Stroka D., Fey M.F. NDRG1/2 expression is inhibited in primary acute myeloid leukemia. Leuk. Res. 2010, 34:393-398.
193. Ahn J., Chung K.S., Kim D.U., Won M., Kim L., Kim K.S., Nam M., Choi S.J., Kim H.C., Yoon M., Chae S.K., Hoe K.L. Systematic identification of hepatocellular proteins interacting with NS5A of the hepatitis C virus. J. Biochem. Mol. Biol. 2004, 37:741-748.
194. Kitowska A., Pawelczyk T. N-myc downstream regulated 1 gene and its place in the cellular machinery. Acta Biochim. Pol. 2010, 57:15-21.
195. Liu R., Li J., Teng Z., Zhang Z., Xu Y. Overexpressed microRNA-182 promotes proliferation and invasion in prostate cancer PC-3 cells by down-regulating N-myc downstream regulated gene 1 (NDRG1). PLoS One 2013, 8:e68982.
196. Alarcon R., Koumenis C., Geyer R.K., Maki C.G., Giaccia A.J. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res. 1999, 59:6046-6051.
197. Blattner C., Hay T., Meek D.W., Lane D.P. Hypophosphorylation of Mdm2 augments p53 stability. Mol. Cell. Biol. 2002, 22:6170-6182.
198. Wang Q., Li L.H., Gao G.D., Wang G., Qu L., Li J.G., Wang C.M. HIF-1alpha up-regulates NDRG1 expression through binding to NDRG1 promoter, leading to proliferation of lung cancer A549 cells. Mol. Biol. Rep. 2013, 40:3723-3729.
199. Inagaki Y., Tang W., Xu H.L., Guo Q., Mafune K., Konishi T., Nakata M., Sugawara Y., Kokudo N. Localization of N-myc downstream-regulated gene 1 in gastric cancer tissue. Dig. Liver Dis. 2009, 41:96-103.
200. Zheng Y., Wang L.S., Xia L., Han Y.H., Liao S.H., Wang X.L., Cheng J.K., Chen G.Q. NDRG1 is down-regulated in the early apoptotic event induced by camptothecin analogs: the potential role in proteolytic activation of PKC delta and apoptosis. Proteomics 2009, 9:2064-2075.
201. Li X., Sakamoto K., Takahashi Y., Nakashima T. Overexpression of Cap43 gene in supraglottic laryngeal squamous cell carcinoma. J. Laryngol. Otol. Suppl. 2009, 11-17.
202. Redmond K.L., Crawford N.T., Farmer H., D'Costa Z.C., O'Brien G.J., Buckley N.E., Kennedy R.D., Johnston P.G., Harkin D.P., Mullan P.B. T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells. Oncogene 2010, 29:3252-3262.
203. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
204. Di Cristofano A., Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell 2000, 100:387-390.
205. Davies M.A., Kim S.J., Parikh N.U., Dong Z., Bucana C.D., Gallick G.E. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin. Cancer Res. 2002, 8:1904-1914.
206. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., Cordon-Cardo C., Pandolfi P.P. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
207. He J., de la Monte S., Wands J.R. The p85beta regulatory subunit of PI3K serves as a substrate for PTEN protein phosphatase activity during insulin mediated signaling. Biochem. Biophys. Res. Commun. 2010, 397:513-519.
208. Chow J.Y., Cabral J.A., Chang J., Carethers J.M. TGFbeta modulates PTEN expression independently of SMAD signaling for growth proliferation in colon cancer cells. Cancer Biol. Ther. 2008, 7:1694-1699.
209. Chalhoub N., Baker S.J. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 2009, 4:127-150.
210. Jiang B.H., Liu L.Z. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv. Cancer Res. 2009, 102:19-65.
211. Stothard P. The sequence manipulation suite: JavaScript programs for analyzing and formatting protein and DNA sequences. Biotechniques 2000, 28(1102):1104.
212. Quandt K., Frech K., Karas H., Wingender E., Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res. 1995, 23:4878-4884.
213. Assinder S.J., Dong Q., Kovacevic Z., Richardson D.R. The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem. J. 2009, 417:411-421.
214. Chen J., Li S., Yang Z., Lu G., Hu H. Correlation between NDRG1 and PTEN expression in endometrial carcinoma. Cancer Sci. 2008, 99:706-710.
215. Li S., Chen J., Yang Z., Lu G., Tang H., Hu H. N-myc downstream-regulated gene 1 as a downregulated target gene of PTEN in the controlling of tumourigenesis in endometrioid carcinoma. Indian J. Med. Res. 2008, 127:453-459.
216. Sun H., Enomoto T., Fujita M., Wada H., Yoshino K., Ozaki K., Nakamura T., Murata Y. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am. J. Clin. Pathol. 2001, 115:32-38.
217. Tashiro H., Blazes M.S., Wu R., Cho K.R., Bose S., Wang S.I., Li J., Parsons R., Ellenson L.H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997, 57:3935-3940.
218. Minaguchi T., Yoshikawa H., Oda K., Ishino T., Yasugi T., Onda T., Nakagawa S., Matsumoto K., Kawana K., Taketani Y. PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin. Cancer Res. 2001, 7:2636-2642.
219. Henriksson M., Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv. Cancer Res. 1996, 68:109-182.
220. Nesbit C.E., Tersak J.M., Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene 1999, 18:3004-3016.
221. Oster S.K., Ho C.S., Soucie E.L., Penn L.Z. The myc oncogene: MarvelouslY Complex. Adv. Cancer Res. 2002, 84:81-154.
222. Facchini L.M., Penn L.Z. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J. 1998, 12:633-651.
223. Blackwood E.M., Eisenman R.N. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991, 251:1211-1217.
224. Wenzel A., Cziepluch C., Schurmann J., Schwab M. The N-myc oncoprotein is a transcriptional activator and associates with max and RB1 proteins. Prog. Clin. Biol. Res. 1994, 385:59-66.
225. Wenzel A., Cziepluch C., Hamann U., Schurmann J., Schwab M. The N-Myc oncoprotein is associated in vivo with the phosphoprotein Max(p20/22) in human neuroblastoma cells. EMBO J. 1991, 10:3703-3712.
226. Alex R., Sozeri O., Meyer S., Dildrop R. Determination of the DNA sequence recognized by the bHLH-zip domain of the N-Myc protein. Nucleic Acids Res. 1992, 20:2257-2263.
227. Lakaye B., Makarchikov A.F., Wins P., Margineanu I., Roland S., Lins L., Aichour R., Lebeau L., El Moualij B., Zorzi W., Coumans B., Grisar T., Bettendorff L. Human recombinant thiamine triphosphatase: purification, secondary structure and catalytic properties. Int. J. Biochem. Cell Biol. 2004, 36:1348-1364.
228. Angst E., Dawson D.W., Stroka D., Gloor B., Park J., Candinas D., Reber H.A., Hines O.J., Eibl G. N-myc downstream regulated gene-1 expression correlates with reduced pancreatic cancer growth and increased apoptosis in vitro and in vivo. Surgery 2011, 149:614-624.
229. Jiang K., Shen Z., Ye Y., Yang X., Wang S. A novel molecular marker for early detection and evaluating prognosis of gastric cancer: N-myc downstream regulated gene-1 (NDRG1). Scand. J. Gastroenterol. 2010, 45:898-908.
230. Liu W., Iiizumi-Gairani M., Okuda H., Kobayashi A., Watabe M., Pai S.K., Pandey P.R., Xing F., Fukuda K., Modur V., Hirota S., Suzuki K., Chiba T., Endo M., Sugai T., Watabe K. KAI1 gene is engaged in NDRG1 gene-mediated metastasis suppression through the ATF3-NFkappaB complex in human prostate cancer. J. Biol. Chem. 2011, 286:18949-18959.
231. Lai L.C., Su Y.Y., Chen K.C., Tsai M.H., Sher Y.P., Lu T.P., Lee C.Y., Chuang E.Y. Down-regulation of NDRG1 promotes migration of cancer cells during reoxygenation. PLoS One 2011, 6:e24375.
232. Lv X.H., Chen J.W., Zhao G., Feng Z.Z., Yang D.H., Sun W.W., Fan J.S., Zhu G.H. N-myc downstream-regulated gene 1/Cap43 may function as tumor suppressor in endometrial cancer. J. Cancer Res. Clin. Oncol. 2012, 138:1703-1715.
233. Said H.M., Polat B., Staab A., Hagemann C., Stein S., Flentje M., Theobald M., Katzer A., Vordermark D. Rapid detection of the hypoxia-regulated CA-IX and NDRG1 gene expression in different glioblastoma cells in vitro. Oncol. Rep. 2008, 20:413-419.
234. Said H.M., Stein S., Hagemann C., Polat B., Staab A., Anacker J., Schoemig B., Theobald M., Flentje M., Vordermark D. Oxygen-dependent regulation of NDRG1 in human glioblastoma cells in vitro and in vivo. Oncol. Rep. 2009, 21:237-246.
235. Kawahara A., Akiba J., Hattori S., Yamaguchi T., Abe H., Taira T., Ureshino H., Murakami Y., Watari K., Koufuji K., Shirouzu K., Kuwano M., Ono M., Kage M. Nuclear expression of N-myc downstream regulated gene 1/Ca(2+)-associated protein 43 is closely correlated with tumor angiogenesis and poor survival in patients with gastric cancer. Exp. Ther. Med. 2011, 2:471-479.
236. Sun J., Zhang D., Zheng Y., Zhao Q., Zheng M., Kovacevic Z., Richardson D.R. Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway. Mol. Pharmacol. 2013, 83:454-469.
237. Dominguez R., Holmes K.C. Actin structure and function. Annu. Rev. Biophys. 2011, 40:169-186.
238. Watanabe N., Kato T., Fujita A., Ishizaki T., Narumiya S. Cooperation between mDia1 and ROCK in Rho-induced actin reorganization. Nat. Cell Biol. 1999, 1:136-143.
239. Frisca F., Crombie D.E., Dottori M., Goldshmit Y., Pebay A. Rho/ROCK pathway is essential to the expansion, differentiation, and morphological rearrangements of human neural stem/progenitor cells induced by lysophosphatidic acid. J. Lipid Res. 2013, 54:1192-1206.
240. Jeong K.J., Park S.Y., Cho K.H., Sohn J.S., Lee J., Kim Y.K., Kang J., Park C.G., Han J.W., Lee H.Y. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene 2012, 31:4279-4289.
241. Ohta T., Takahashi T., Shibuya T., Amita M., Henmi N., Takahashi K., Kurachi H. Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1alpha in human ovarian cancer cells. Cancer Biol. Ther. 2012, 13:25-33.
242. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
243. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1:27-31.
244. Nishida T. Angiogenesis, which is essential for cancer growth, is a diagnostic and therapeutic target. J. Gastroenterol. 2005, 40:320-321.
245. Hosoi F., Izumi H., Kawahara A., Murakami Y., Kinoshita H., Kage M., Nishio K., Kohno K., Kuwano M., Ono M. N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of kappaB kinase beta expression. Cancer Res. 2009, 69:4983-4991.
246. Fang J., Ding M., Yang L., Liu L.Z., Jiang B.H. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell. Signal. 2007, 19:2487-2497.
247. Murakami Y., Watari K., Shibata T., Uba M., Ureshino H., Kawahara A., Abe H., Izumi H., Mukaida N., Kuwano M., Ono M. N-myc Downstream-regulated Gene 1 promotes tumor inflammatory angiogenesis through JNK activation and autocrine loop of interleukin-1alpha by human gastric cancer cells. J. Biol. Chem. 2013, 288:25025-25037.
248. Richardson A., Kovacevic Z., Richardson D.R. Iron chelation: inhibition of key signaling pathways in the induction of the epithelial mesenchymal transition in pancreatic cancer and other tumors. Crit. Rev. Oncog. 2013, 18:409-434.
249. Liu Y.L., Bai W.T., Luo W., Zhang D.X., Yan Y., Xu Z.K., Zhang F.L. Downregulation of NDRG1 promotes invasion of human gastric cancer AGS cells through MMP-2. Tumor Biol. 2011, 32:99-105.
250. Ureshino H., Murakami Y., Watari K., Izumi H., Kawahara A., Kage M., Arao T., Nishio K., Yanagihara K., Kinoshita H., Kuwano M., Ono M. N-myc downstream regulated gene 1 (NDRG1) promotes metastasis of human scirrhous gastric cancer cells through epithelial mesenchymal transition. PLoS One 2012, 7:e41312.
251. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007, 26:225-239.
252. Caruso R.P., Levinson B., Melamed J., Wieczorek R., Taneja S., Polsky D., Chang C., Zeleniuch-Jacquotte A., Salnikow K., Yee H., Costa M., Osman I. Altered N-myc downstream-regulated gene 1 protein expression in African-American compared with caucasian prostate cancer patients. Clin. Cancer Res. 2004, 10:222-227.
253. Motwani M., Sirotnak F.M., She Y., Commes T., Schwartz G.K. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res. 2002, 62:3950-3955.
254. Yu Y., Wong J., Lovejoy D.B., Kalinowski D.S., Richardson D.R. Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin. Cancer Res. 2006, 12:6876-6883.
255. Merlot A.M., Kalinowski D.S., Richardson D.R. Novel chelators for cancer treatment: where are we now?. Antioxid. Redox Signal. 2013, 18:973-1006.
256. Richardson D.R., Tran E.H., Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995, 86:4295-4306.
257. Whitnall M., Howard J., Ponka P., Richardson D.R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:14901-14906.
258. Liu W., Xing F., Iiizumi-Gairani M., Okuda H., Watabe M., Pai S.K., Pandey P.R., Hirota S., Kobayashi A., Mo Y.Y., Fukuda K., Li Y., Watabe K. N-myc downstream regulated gene 1 modulates Wnt-beta-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol. Med. 2012, 4:93-108.
259. Yu Y., Suryo Rahmanto Y., Richardson D.R. Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. Br. J. Pharmacol. 2012, 165:148-166.
260. Kovacevic Z., Kalinowski D.S., Lovejoy D.B., Yu Y., Suryo Rahmanto Y., Sharpe P.C., Bernhardt P.V., Richardson D.R. The medicinal chemistry of novel iron chelators for the treatment of cancer. Curr. Top. Med. Chem. 2011, 11:483-499.
261. Yuan J., Lovejoy D.B., Richardson D.R. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 2004, 104:1450-1458.
262. Lovejoy D.B., Sharp D.M., Seebacher N., Obeidy P., Prichard T., Stefani C., Basha M.T., Sharpe P.C., Jansson P.J., Kalinowski D.S., Bernhardt P.V., Richardson D.R. Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. J. Med. Chem. 2012, 55:7230-7244.
263. Page R.D. TreeView: an application to display phylogenetic trees on personal computers. Comput. Appl. Biosci. 1996, 12:357-358.
264. Boutet E., Lieberherr D., Tognolli M., Schneider M., Bairoch A. UniProtKB/Swiss-Prot. Methods Mol. Biol. 2007, 406:89-112.
265. The Consortium UniProt Update on activities at the Universal Protein Resource (UniProt) in 2013. Nucleic Acids Res. 2013, 41:D43-D47.
266. Edgar R.C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004, 32:1792-1797.
267. Edgar R.C. MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinforma. 2004, 5:113.
268. Guermeur Y., Geourjon C., Gallinari P., Deleage G. Improved performance in protein secondary structure prediction by inhomogeneous score combination. Bioinformatics 1999, 15:413-421.
269. Combet C., Jambon M., Deleage G., Geourjon C. Geno3D: automatic comparative molecular modelling of protein. Bioinformatics 2002, 18:213-214.
270. Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem. Mol. Biol. Educ. 2006, 34:255-261.
271. Steinbeck C., Han Y., Kuhn S., Horlacher O., Luttmann E., Willighagen E. The Chemistry Development Kit (CDK): an open-source Java library for chemo- and bioinformatics. J. Chem. Inf. Comput. Sci. 2003, 43:493-500.
272. Fotovati A., Abu-Ali S., Kage M., Shirouzu K., Yamana H., Kuwano M. N-myc downstream-regulated gene 1 (NDRG1) a differentiation marker of human breast cancer. Pathol. Oncol. Res. 2011, 17:525-533.
273. Salnikow K., Blagosklonny M.V., Ryan H., Johnson R., Costa M. Carcinogenic nickel induces genes involved with hypoxic stress. Cancer Res. 2000, 60:38-41.
274. Salnikow K., Costa M., Figg W.D., Blagosklonny M.V. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer. Cancer Res. 2000, 60:5630-5634.
275. Hu C.J., Wang L.Y., Chodosh L.A., Keith B., Simon M.C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell. Biol. 2003, 23:9361-9374.
276. Salnikow K., Zhou D., Wang C., Costa M. Treatment of human lung cells with calcium channel blocker nickel chloride resulted in elevation of intracellular calcium and expression of a novel gene. Toxicologist 1998, 42:320.
277. Zhou D., Costa M. Identification and cloning of a gene specifically induced by nickel(II) exposure. Toxicologist 1997, 36:39.
278. Salnikow K., An W.G., Melillo G., Blagosklonny M.V., Costa M. Nickel-induced transformation shifts the balance between HIF-1 and p53 transcription factors. Carcinogenesis 1999, 20:1819-1823.
279. Wei D., Peng J.J., Gao H., Li H., Li D., Tan Y., Zhang T. Digoxin Downregulates NDRG1 and VEGF through the Inhibition of HIF-1alpha under Hypoxic Conditions in Human Lung Adenocarcinoma A549 Cells. Int. J. Mol. Sci. 2013, 14:7273-7285.
280. Fotovati A., Fujii T., Yamaguchi M., Kage M., Shirouzu K., Oie S., Basaki Y., Ono M., Yamana H., Kuwano M. 17Beta-estradiol induces down-regulation of Cap43/NDRG1/Drg-1, a putative differentiation-related and metastasis suppressor gene, in human breast cancer cells. Clin. Cancer Res. 2006, 12:3010-3018.
281. Ring B.Z., Seitz R.S., Beck R., Shasteen W.J., Tarr S.M., Cheang M.C., Yoder B.J., Budd G.T., Nielsen T.O., Hicks D.G., Estopinal N.C., Ross D.T. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J. Clin. Oncol. 2006, 24:3039-3047.
282. Mao X.Y., Fan C.F., Wei J., Liu C., Zheng H.C., Yao F., Jin F. Increased N-myc downstream-regulated gene 1 expression is associated with breast atypia-to-carcinoma progression. Tumor Biol. 2011, 32:1271-1276.
283. Fujii T., Yokoyama G., Takahashi H., Namoto R., Nakagawa S., Toh U., Kage M., Shirouzu K., Kuwano M. Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer. Breast Cancer 2008, 15:73-78.
284. Fujii T., Yokoyama G., Takahashi H., Toh U., Kage M., Ono M., Shirouzu K., Kuwano M. Preclinical and clinical studies of novel breast cancer drugs targeting molecules involved in protein kinase C signaling, the putative metastasis-suppressor gene Cap43 and the Y-box binding protein-1. Curr. Med. Chem. 2008, 15:528-537.
285. Nagai M.A., Gerhard R., Fregnani J.H., Nonogaki S., Rierger R.B., Netto M.M., Soares F.A. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res. Treat. 2011, 126:1-14.
286. Song Y., Oda Y., Hori M., Kuroiwa K., Ono M., Hosoi F., Basaki Y., Tokunaga S., Kuwano M., Naito S., Tsuneyoshi M. N-myc downstream regulated gene-1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin. Hum. Pathol. 2010, 41:214-222.
287. Zhao D., Chen M., Jiang C., Gassimou B., Liu Z., Cao Z. The regulatory role of colorectal adenocarcinoma hypoxia-inducible factor-1α in the expression of N-myc down-stream regulative Gene 1. J. Anim. Vet. Adv. 2012, 11:4121-4126.
288. Zhao D., Liu Z., Jiang C., Gassimou B., Wu K., Wu J. Regulation of HIF-1α to expression of N-myc downstream regulated Gene 1 in colorectal carcinoma, Wuhan University. J. Nat. Sci. 2007, 12:563-568.
289. Mao Z., Sun J., Feng B., Ma J., Zang L., Dong F., Zhang D., Zheng M. The metastasis suppressor, N-myc downregulated gene 1 (NDRG1), is a prognostic biomarker for human colorectal cancer. PLoS One 2013, 8:e68206.
290. Zhang S.B., Song S.P., Li B., Zhou Y.S., Zhang Y.D. Expression of N-myc downstream-regulated gene 1 in primary gallbladder carcinoma and its correlation with clinicopathological features and clinical outcome. Med. Oncol. 2012, 29:1866-1872.
291. Sibold S., Roh V., Keogh A., Studer P., Tiffon C., Angst E., Vorburger S.A., Weimann R., Candinas D., Stroka D. Hypoxia increases cytoplasmic expression of NDRG1, but is insufficient for its membrane localization in human hepatocellular carcinoma. FEBS Lett. 2007, 581:989-994.
292. Dos Santos M., da Cunha Mercante A.M., Nunes F.D., Leopoldino A.M., de Carvalho M.B., Gazito D., Lopez R.V., Chiappini P.B., de Carvalho Neto P.B., Fukuyama E.E., G.Head Neck Genome Project, Tajara E.H., Louro I.D., da Silva A.M. Prognostic significance of NDRG1 expression in oral and oropharyngeal squamous cell carcinoma. Mol. Biol. Rep. 2012, 39:10157-10165.
293. Angst E., Sibold S., Tiffon C., Weimann R., Gloor B., Candinas D., Stroka D. Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer. Br. J. Cancer 2006, 95:307-313.
294. Fotovati A., Abu-Ali S., Sugita Y., Nakamura Y. Expression of N-myc downstream regulated gene 1 (NDRG1) in central neurocytoma. J. Clin. Neurosci. 2011, 18:1383-1385.
295. Azuma K., Kawahara A., Hattori S., Taira T., Tsurutani J., Watari K., Shibata T., Murakami Y., Takamori S., Ono M., Izumi H., Kage M., Yanagawa T., Nakagawa K., Hoshino T., Kuwano M. NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer. J. Thorac. Oncol. 2012, 7:779-789.
296. Fan C., Yu J., Liu Y., Xu H., Wang E. Increased NDRG1 expression is associated with advanced T stages and poor vascularization in non-small cell lung cancer. Pathol. Oncol. Res. 2012, 18:549-556.
297. Wang D., Tian X., Jiang Y. NDRG1/Cap43 overexpression in tumor tissues and serum from lung cancer patients. J. Cancer Res. Clin. Oncol. 2012, 138:1813-1820.
298. Hosoya N., Sakumoto M., Nakamura Y., Narisawa T., Bilim V., Motoyama T., Tomita Y., Kondo T. Proteomics identified nuclear N-myc downstream-regulated gene 1 as a prognostic tissue biomarker candidate in renal cell carcinoma. Biochim. Biophys. Acta 2013, 1834:2630-2639.
299. Kehlen A., Lendeckel U., Dralle H., Langner J., Hoang-Vu C. Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res. 2003, 63:8500-8506.
300. Gerhard R., Nonogaki S., Fregnani J.H., Soares F.A., Nagai M.A. NDRG1 protein overexpression in malignant thyroid neoplasms. Clinics (Sao Paulo) 2010, 65:757-762.